本文選題：前列腺癌　切入點(diǎn)：實(shí)驗(yàn)室診斷　出處：《中華男科學(xué)雜志》2017年04期

【摘要】：近年來(lái)前列腺癌的發(fā)病率呈上升趨勢(shì),是導(dǎo)致患惡性腫瘤男性死亡的主要原因之一,其早期癥狀不明顯,20%的患者初診時(shí)已發(fā)生轉(zhuǎn)移。早期診斷率低是我國(guó)前列腺癌病死率高于歐美國(guó)家的主要原因。前列腺癌患者的血液、尿液、精液中存在著特異性和敏感性較高的診斷標(biāo)志物,如早期前列腺癌抗原、ERG蛋白、基質(zhì)金屬蛋白酶9、GSTP1甲基化等,聯(lián)合檢測(cè)可以提高前列腺癌早期診斷率,做到早發(fā)現(xiàn)、早治療,為患者的治療提供機(jī)會(huì),進(jìn)一步延長(zhǎng)患者的生存期。
[Abstract]:In recent years, the incidence of prostate cancer is on the rise, which is one of the main causes of death in men with malignant tumor.The low early diagnosis rate is the main reason that the fatality rate of prostate cancer in China is higher than that in Europe and America.In the blood, urine and semen of prostate cancer patients, there are some specific and sensitive diagnostic markers, such as early prostate cancer antigen ERG protein, matrix metalloproteinase 9 GSTP1 methylation, etc.Combined detection can improve the rate of early diagnosis of prostate cancer, early detection, early treatment, for the treatment of patients with opportunities to further prolong the survival of patients.
【作者單位】： 天津中醫(yī)藥大學(xué)第一附屬醫(yī)院腫瘤科;
【基金】：天津市衛(wèi)生局課題(13081) 天津市科學(xué)技術(shù)委員會(huì)科技支撐計(jì)劃項(xiàng)目(12ZCDZSY17000)~~
【分類(lèi)號(hào)】：R737.25
，

本文編號(hào)：1717011